Clinical Professor of Medicine, University Tex SW Dallas
Rheumatology
Dr. Roy M. Fleischmann, MD
|
|
Give Review
Roy M. Fleischmann works in the field of Rheumatology. He researched medicine at Mount Sinai School of Medicine. He received 2 awards: "Regional Top Doctor" and "Super Doctor". Doctor Roy M. Fleischmann, MD is also a published physician. He has 54 publication published. The most recent publication is: Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III. Roy M. Fleischmann accepts Medicare payments and is registered with Medicare.gov.
Publications
- Efficacy and safety of tofacitinib in US and non-US rheumatoid Arthritis patients: pooled analyses of phase II and III.
- Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological Disease-modifying antirheumatic drugs.
- Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years.
- Sarilumab plus methotrexate in patients with active rheumatoid Arthritis and inadequate response to methotrexate: Results of a phase III study.
- Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid Arthritis.
- Rheumatoid Arthritis: Developing new oral targeted therapies for RA can be challenging.
- Infliximab efficacy in rheumatoid Arthritis after an inadequate response to etanercept or adalimumab: results of a target-driven active switch study.
- A Double-Blind, Placebo-Controlled, Randomized, 12-Week, Dose-Ranging Study of VX-509 (Decernotinib), an Oral Selective Janus Kinase 3 (JAK3) Inhibitor, as Monotherapy...
- Response to: 'Is there a need for new thresholds to define remission and low Disease activity by Disease Activity Score 28 calculated with C reactive protein? Real lif...
- Response to H Zeidler's comments on the CONCERTO study.
- Tofacitinib versus methotrexate in rheumatoid Arthritis.
- Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in Gout patients with hyperuricaemia.
- Effect of golimumab on carotid atherosclerotic Disease measures and cardiovascular events in inflammatory arthritides.
- Adjustment of therapy in rheumatoid Arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the r...
- Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients w...
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid Arthritis: two-year efficacy and safety findings from AMPLE trial.
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic Arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study ...
- Updated consensus statement on biological agents for the treatment of rheumatic Diseases, 2012.
- Back to the future: oral small molecule kinases.
- Evaluation of Serum Biomarkers Associated with Radiographic Progression in Methotrexate-naive Rheumatoid Arthritis Patients Treated with Methotrexate or Golimumab.
- Methodological aspects and the interpretation of clinical trial data: lessons from the TEAR trial.
- Tocilizumab Inhibits Structural Joint Damage and Improves Physical Function in Patients with Rheumatoid Arthritis and Inadequate Responses to Methotrexate: LITHE Study...
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid Arthritis: findings of a phase IIIb, multinational, prospective, randomized study.
- Clinical, functional and radiographic consequences of achieving stable low Disease activity and remission with adalimumab plus methotrexate or methotrexate alone in ea...
- Validation of a novel multibiomarker test to assess rheumatoid Arthritis disease activity.
- Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid Arthritis with an inadequate response to TNF inhibitors.
- Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid Arthritis: results from the REALISTIC phase IIIb study.
- Placebo-controlled trial of tofacitinib monotherapy in rheumatoid Arthritis.
- Novel small-molecular therapeutics for rheumatoid Arthritis.
- Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Ra...
- Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid Arthritis.
- Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active Rheumatoid...
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid Arthritis failing previous disease-modifying antirheumatic therapy: the...
- Safety of biologic therapy in rheumatoid Arthritis and other autoimmune diseases: focus on rituximab.
- Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with Rheumatoid arthriti...
- Unresolved issues in identifying and overcoming inadequate response in rheumatoid Arthritis: weighing the evidence.
- Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid Arthritis.
- Comparison of the efficacy of biologic therapy for rheumatoid Arthritis: can the clinical trials be accurately compared?
- Treatment of early rheumatoid Arthritis.
- Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid Arthritis.
- Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid Arthritis.
- Is there a need for new therapies for rheumatoid Arthritis?
- Considerations with the use of biological therapy in the treatment of rheumatoid Arthritis.
- Etanercept (Enbrel) in patients with rheumatoid Arthritis with recent onset versus established disease: improvement in disability.
- Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of Rheumatoid arthriti...
- Etanercept added to background methotrexate therapy in patients with rheumatoid Arthritis: continued observations.
- Response to etanercept (Enbrel) in elderly patients with rheumatoid Arthritis: a retrospective analysis of clinical trial results.
- Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid Arthritis: A large, international, multicenter, placebo-co...
- Examining the efficacy of biologic therapy: are there real differences?
- Etanercept versus methotrexate in patients with early rheumatoid Arthritis: two-year radiographic and clinical outcomes.
- Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid Arthritis and inadequate responses to ...
- Effect of certolizumab pegol over 96 weeks in patients with psoriatic Arthritis with and without prior antitumour necrosis factor exposure.
- Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse Rheumatoid...
Schools
SUNY Downstate Medical Center College Of Medicine
Maimonides Med Center
Mt Sinai Hospital
Colum Presby Med Center
Procedures Preformed
- Joint Drainage
- Steroid Injection
Conditions Treated
- Ankylosing Spondylitis
- Arthritis
- Bursitis
- Carpal Tunnel Syndrome
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- Regional Top Doctor
- Super Doctor
Education
-
Mount Sinai School of Medicine -
Maimonides Medical Center -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
Medical City Dallas Hospital -
University of Texas Southwestern Medical Center
Drug Facts
| NPI NUMBER | 1467451146 | |
| NPPES Provider LastName | FLEISCHMANN | |
| NPPES Provider FirstName | ROY | |
| NPPES Provider ZIPCode | 752314388 | |
| NPPES Provider State | TX | |
| Specialty Description | Rheumatology | |
| Total Claim Count | 2248.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 182.0 | |
| Percent Opioid Claims | 8.1 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467451146 |
| Last Name Of The Provider | FLEISCHMANN |
| First Name Of The Provider | ROY |
| View All |
Similar Doctors
|
|
Dr. John J. Cush, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Laura Tarter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Xiaying S. Zhu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andreas M. Reimold, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Allan D. Duby, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Margarita Fallena, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharad Lakhanpal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth B. Solow, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica Procter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashmi Arora, MD |
|
|
Dr. Imran Iqbal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pedro Stastny, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Archana G. Srinivas, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Julia A. Dilliard |